Clinical Trials: Clinical Trials in USA

Electronic Source Data (eSource) Acceptance by the FDA in U.S. Clinical Trials

Posted on digi By digi

Sponsors should: (1) validate eSource systems thoroughly; (2) maintain robust vendor oversight; (3) integrate EHR-EDC data flows with reconciliation checks; (4) train investigators on system use; (5) ensure Part 11-compliant audit trails; (6) harmonize global standards with EMA/ICH expectations; (7) prepare for FDA inspections with complete documentation; (8) pilot-test systems before large-scale deployment; and (9) maintain participant privacy protections at all times.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

The CRO Landscape in the United States: Opportunities and Challenges in Clinical Trials

Posted on digi By digi

Sponsors should: (1) conduct thorough CRO qualification and audits; (2) define clear contracts and responsibility matrices; (3) maintain robust oversight and monitoring; (4) implement centralized risk-based monitoring; (5) require validated systems and audit trails; (6) engage CROs early in trial design; (7) maintain transparency through dashboards and KPIs; (8) align CRO performance with CAPA programs; (9) ensure CRO staff receive continuous training; and (10) prepare for FDA and global inspections at all times.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Pharmacovigilance Obligations in U.S. Clinical Trials

Posted on digi By digi

Sponsors should: (1) maintain validated pharmacovigilance systems; (2) establish SOPs for SAE/SUSAR reporting; (3) train investigators and CRO staff; (4) harmonize global reporting with FDA requirements; (5) conduct regular audits; (6) engage independent DMCs for high-risk trials; (7) ensure IRB communication; (8) document CAPAs for findings; (9) integrate pharmacovigilance into TMFs; and (10) maintain inspection readiness at all times.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Fast Track, Breakthrough, and Accelerated Approvals: Impact on U.S. Clinical Trials

Posted on digi By digi

Sponsors should: (1) engage FDA early to confirm eligibility; (2) design trials with validated surrogate endpoints; (3) maintain robust pharmacovigilance for post-market monitoring; (4) allocate resources for confirmatory studies; (5) strengthen CRO/vendor oversight; (6) plan global alignment strategies; (7) ensure transparent communication with IRBs and investigators; and (8) prepare for heightened FDA scrutiny during and after approval.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

FDA Expectations for Trial Master File (TMF) in U.S. Clinical Trials

Posted on digi By digi

Sponsors should: (1) adopt the DIA TMF Reference Model; (2) validate eTMFs for Part 11 compliance; (3) establish SOPs for document management; (4) conduct periodic audits; (5) ensure contemporaneous filing; (6) monitor CRO TMF compliance; (7) maintain inspection readiness; (8) train TMF staff regularly; (9) implement version control and reconciliation processes; and (10) retain TMFs per regulatory requirements.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Oncology Basket Trials Conducted in the United States: Regulatory and Operational Perspectives

Posted on digi By digi

Sponsors should: (1) validate biomarkers early; (2) engage FDA proactively; (3) adopt adaptive statistical designs; (4) harmonize global trial protocols; (5) ensure robust genomic screening partnerships; (6) maintain TMF documentation for all cohorts; (7) provide investigator training on eligibility criteria; (8) address diversity in recruitment; and (9) implement robust oversight of CROs and vendors.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Post-COVID Shifts in Clinical Research in the United States

Posted on digi By digi

Sponsors should: (1) integrate decentralized tools into protocol design; (2) validate digital health systems; (3) train staff on remote monitoring; (4) strengthen site infrastructure; (5) ensure HIPAA compliance in remote data collection; (6) prepare contingency plans for disruptions; (7) harmonize global trial strategies; and (8) maintain transparent communication with FDA on novel trial designs.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Data Integrity Observations from FDA Clinical Inspections in the United States

Posted on digi By digi

Sponsors should: (1) embed ALCOA+ principles into SOPs; (2) validate all electronic systems; (3) conduct routine audits of CROs and sites; (4) train staff in GCP and data integrity; (5) implement robust SDV strategies; (6) maintain contemporaneous documentation; (7) monitor audit trails; (8) reconcile discrepancies promptly; (9) ensure eTMFs are inspection-ready; and (10) maintain CAPA programs for deficiencies.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

FDA Guidance on Decentralized Clinical Trials (DCTs) in the United States

Posted on digi By digi

Sponsors should: (1) validate all digital tools; (2) prepare clear SOPs for decentralized activities; (3) train staff and patients; (4) ensure HIPAA and Part 11 compliance; (5) maintain robust vendor oversight; (6) use hybrid models to balance efficiency and oversight; (7) engage FDA early on novel designs; (8) implement risk-based monitoring; and (9) maintain inspection-ready documentation at all times.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

The Role of Veterans Affairs Hospitals in U.S. Clinical Research

Posted on digi By digi

Sponsors should: (1) engage VA research offices early; (2) prepare for extended contracting and IRB processes; (3) align trial designs with VA patient needs; (4) collaborate with academic affiliates for broader expertise; (5) validate use of VA data systems for regulatory purposes; (6) ensure staff training in FDA and VA-specific requirements; (7) maintain transparent communication with FDA; and (8) implement robust monitoring and CAPA systems for compliance.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials